Document Detail


No HOPE without proof: do ARBs meet the standard for cardiovascular protection?
MedLine Citation:
PMID:  18449379     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Blockade of the renin-angiotensin system (RAS) by angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) plays an important role in the protection and prevention of cardiovascular disease. The Heart Outcomes Prevention Evaluation (HOPE) study established the significant effect of ACE inhibition on cardiovascular morbidity and mortality beyond blood pressure control. Smaller studies have demonstrated the efficacy of ARBs. In addition, a recent analysis from the Blood Pressure Lowering Treatment Trialists' Collaboration showed that ARB-based and ACE inhibitor-based treatment regimens were comparable in terms of the odds ratio for stroke and heart failure, independent of blood pressure reduction. There is an emerging body of evidence to suggest that a combination approach to RAS blockade with an ARB and an ACE inhibitor may further improve cardiovascular outcome compared with monotherapy with either agent alone. The large-scale ONgoing Telmisartan Alone or in combination with Ramipril Global Endpoint Trial (ONTARGET), comparing high-dose ramipril (HOPE study dosage) with telmisartan or a combination of the two, should provide important insight into the benefits of RAS blockade intervention. The results of ONTARGET are anticipated to be available in 2008.
Authors:
Peter Sleight; Anne Jakobsen; Jose Heroys; Ann Ralph; Tomas Rees; Michael Shaw
Related Documents :
6986949 - Effects of an angiotensin-converting enzyme inhibitor (captopril) on blood pressure in ...
2643489 - Importance of venodilatation in prevention of left ventricular dilatation after chronic...
217289 - Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive pat...
15723969 - Effect of treatment with candesartan or enalapril on subcutaneous small artery structur...
9990539 - Sub-antihypertensive doses of ramipril normalize sarcoplasmic reticulum calcium atpase ...
11320369 - Adept: addition of the at1 receptor antagonist eprosartan to ace inhibitor therapy in c...
15307539 - Juxtaaortic counterpulsation: comparison with intraaortic counterpulsation in an animal...
10198379 - Central and peripheral administration of endothelin-1 induces an increase in blood pres...
988549 - Norepinephrine and isoprenaline induced changes of peripheral blood flow acceleration c...
Publication Detail:
Type:  Journal Article; Meta-Analysis; Review     Date:  2008-03-26
Journal Detail:
Title:  Medscape journal of medicine     Volume:  10 Suppl     ISSN:  1934-1997     ISO Abbreviation:  Medscape J Med     Publication Date:  2008  
Date Detail:
Created Date:  2008-05-01     Completed Date:  2008-06-05     Revised Date:  2013-06-05    
Medline Journal Info:
Nlm Unique ID:  101462763     Medline TA:  Medscape J Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S6     Citation Subset:  IM    
Affiliation:
Department of Cardiovascular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom. peter.sleight@cardiov.ox.ac.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin II Type 1 Receptor Blockers / administration & dosage*
Angiotensin-Converting Enzyme Inhibitors / administration & dosage*
Cardiotonic Agents / administration & dosage*
Cardiovascular Diseases / mortality*,  prevention & control*
Clinical Trials as Topic / statistics & numerical data*
Evidence-Based Medicine / statistics & numerical data
Humans
Practice Guidelines as Topic*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Cardiotonic Agents
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cardiovascular high-risk patients--treat to protect, but whom?
Next Document:  Cardiac and vascular protection: the potential of ONTARGET.